-
慢性阻塞性肺疾病(COPD)是一种以持续气流受限为特征的可以预防和治疗的疾病,其气流受限不完全可逆,呈进行性发展[1],具有较高的发生率和致死率。目前,COPD居全球死亡原因的第4位,在我国40岁以上人群的发生率为8.2%,估计全国每年死亡约100万人,居我国各种死亡原因的第3位[2]。血液高凝状态和微血栓的形成是导致一部分COPD病人急性加重的原因,纤维蛋白原(FIB)和D-二聚体是判断机体血液高凝状态和纤溶亢进的两项重要指标。二氧化碳分压(PCO2)可反映病人的肺泡通气量,反映COPD急性加重期(AECOPD)通气功能、合并呼吸衰竭的严重程度,反映病人病情严重程度。因此本研究对AECOPD病人PCO2和FIB、D-二聚体的相关性进行分析和探讨。现作报道。
-
92例AECOPD病人PCO2水平为(55.17±14.29)mmHg,FIB水平为(4.43±0.92)g/L,D-二聚体水平为(0.69±0.52)mg/L。PCO2增高组FIB、D-二聚体明显高于PCO2正常组(P < 0.01)(见表 1)。FIB和PCO2呈正相关关系(r=0.686,P < 0.05);D二聚体和PCO2呈正相关关系(r=0.741,P < 0.05)。
分组 n FIB/(g/L) D-二聚体/(mg/L) PCO2正常组 41 3.84±0.87 0.45±0.29 PCO2增高组 51 4.90±0.65 0.89±0.58 t — 6.69 4.73 P — <0.01 <0.01 表 1 PCO2正常组、增高组组间凝血指标比较(x±s)
AECOPD病人CO2潴留与凝血指标变化的相关性分析
Correlation analysis of carbon dioxide retention with coagulation index in patients with AECOPD
-
摘要:
目的研究慢性阻塞性肺疾病急性加重期病人(AECOPD)血气分析二氧化碳分压(PCO2)和凝血指标纤维蛋白原(FIB)、D-二聚体的相关性。 方法AECOPD病人排除可能并存对凝血指标有影响的疾病及相关因素者共计92例,分析PCO2与FIB、D-二聚体的相关性。 结果AECOPD病人PCO2增高组FIB、D-二聚体明显高于PCO2正常组(P < 0.01)。PCO2与FIB呈正相关关系(r=0.686,P < 0.05),PCO2与D二聚体呈正相关关系(r=0.741,P < 0.05)。 结论AECOPD病人二氧化碳潴留越严重,凝血功能障碍的发生率越高。 -
关键词:
- 慢性阻塞性肺疾病急性加重期 /
- 二氧化碳分压 /
- 纤维蛋白原 /
- D-二聚体
Abstract:ObjectiveTo study the correlations between the partial pressure of carbon dioxide (PCO2) and levels of fibrinogen (FIB), D-dimmer in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). MethodsExcluding the possible coexisting disease and related factors affecting the coagulation indexes, the correlations between PCO2 and levels of FIB, D-dimmer in 92 patients with AECOPD were analyzed. ResultsThe levels of FIB and D-dimmer of AECOPD patients in PCO2 increasing group were significantly higher than those in normal PCO2 group (P < 0.01).The levels of FIB and D-dimmer were positively correlated with the PCO2 (r=0.686, 0.741, P < 0.05). ConclusionsThe more serious the carbon dioxide retention is, the higher the incidence of coagulation dysfunction is in AECOPD patients. -
表 1 PCO2正常组、增高组组间凝血指标比较(x±s)
分组 n FIB/(g/L) D-二聚体/(mg/L) PCO2正常组 41 3.84±0.87 0.45±0.29 PCO2增高组 51 4.90±0.65 0.89±0.58 t — 6.69 4.73 P — <0.01 <0.01 -
[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中华结核和呼吸杂志, 2013, 36(4):255. doi: 10.3760/cma.j.issn.1001-0939.2013.04.007 [2] 张杰, 张颖, 余其贵, 等.老年慢性阻塞性肺疾病急性发作患者血清中血管内皮因子变化及其意义[J].安徽医药, 2014, 18(1):109. doi: 10.3969/j.issn.1009-6469.2014.01.034 [3] RIZKALLAH J, MAN S F, SIN DD.Prevalence of pulmonary embolism in acute exacerbations of COPD:a systematic review and metaanalysis[J].Chest, 2009, 135(3):786. doi: 10.1378/chest.08-1516 [4] 关伟.慢性阻塞性肺疾病合并肺血栓栓塞症的研究进展[J].心肺血管病杂志, 2012, 31(3):342. doi: 10.3969/j.issn.1007-5062.2012.03.032 [5] 段林立, 张挪富, 刘春丽.慢性阻塞性肺疾病急性加重合并静脉血栓症研究进展[J].中华结核和呼吸杂志, 2016, 39(2):130. doi: 10.3760/cma.j.issn.1001-0939.2016.02.013 [6] VALVI D, MANNINO DM, MVLLEROVA H, et al.Fibrinogen, chronic obstructive pulmonary disease(COPD) and outcomes in two United States cohorts[J].Int J Chron Obstruct Pulmon Dis, 2012, 7:173. [7] MANNINO DM, TAL-SINGER R, LOMAS DA, et al.Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD[J].Chronic Obstr Pulm Dis(Miami), 2015, 2(1):23. [8] DUVOIX A, DICKENS J, HAQ I, et al.Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease[J].Thorax, 2013, 68(7):670. doi: 10.1136/thoraxjnl-2012-201871 [9] FRUCHTER O, YIGLA M, KRAMER MR.D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation[J].Am J Med Sci, 2015, 349(1):29. doi: 10.1097/MAJ.0000000000000332